Immune-based therapies for sarcoma

Sarcoma

Volumn 2011, Issue , 2011, Pages

  Jones, Robin L ^a   Pollack, Seth M ^a   Loggers, Elizabeth T ^a   Rodler, Eve T ^a   Yee, Cassian ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

105 AD7; ALPHA INTERFERON; BETA INTERFERON; BLEOMYCIN; CANCER TESTIS ANTIGEN; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DENDRITIC CELL VACCINE; DOXORUBICIN; EWS FLI 1 PEPTIDE; FLUDARABINE; GAMMA INTERFERON; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IFOSFAMIDE; INTERLEUKIN 2; METHOTREXATE; MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; PHOSPHATIDYLETHANOLAMINE; PROTEIN SYT SSX; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CLINICAL PRACTICE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOXICITY; EWING SARCOMA; FIBROSARCOMA; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; KILLER CELL; LEIOMYOSARCOMA; LEUKOCYTE ACTIVATED KILLER CELL; LOW DRUG DOSE; LYMPHOCYTE TRANSFER; MELANOMA; METASTASIS; MYXOSARCOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THERAPY EFFECT; TUMOR ASSOCIATED LEUKOCYTE; WHOLE BODY RADIATION;

EID: 79953281185     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2011/438940     Document Type: Review

References (51)

1. Schuster S. J., Neelapu S. S., Gause B. L., Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results Journal of Clinical Oncology 2009 27 18S supplement
2. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer New England Journal of Medicine 2010 363 5 411 422
3. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J.M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebb C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 2010 363 8 711 723
4. Maki R. G., Soft tissue sarcoma as a model disease to examine cancer immunotherapy Current Opinion in Oncology 2001 13 4 270 274 (Pubitemid 32578993)
5. Maki R. G., Future directions for immunotherapeutic intervention against sarcomas Current Opinion in Oncology 2006 18 4 363 368 (Pubitemid 44297248)
6. Dillman R., Barth N., Selvan S., Beutel L., De Leon C., DePriest C., Peterson C., Nayak S., Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas Cancer Biotherapy and Radiopharmaceuticals 2004 19 5 581 588 (Pubitemid 39546297)
7. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Annals of Surgery 1989 210 4 474 485 (Pubitemid 19242611)
8. Schwinger W., Klass V., Benesch M., Lackner H., Dornbusch H. J., Sovinz P., Moser A., Schwantzer G., Urban C., Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients Annals of Oncology 2005 16 7 1199 1206 (Pubitemid 41418325)
9. Murray J. L., Kleinerman E. S., Cunningham J. E., Tatom J. R., Andrejcio K., Lepe-Zuniga J., Lamki L. M., Rosenblum M. G., Frost H., Gutterman J. U., Fidler I. J., Krakoff I. H., Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients Journal of Clinical Oncology 1989 7 12 1915 1925 (Pubitemid 20014341)
10. Kleinerman E. S., Jia S. F., Griffin J., Seibel N. L., Benjamin R. S., Jaffe N., Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration Journal of Clinical Oncology 1992 10 8 1310 1316
11. Meyers P. A., Schwartz C. L., Krailo M., Kleinerman E. S., Betcher D., Bernstein M. L., Conrad E., Ferguson W., Gebhardt M., Goorin A. M., Harris M. B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H., Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate Journal of Clinical Oncology 2005 23 9 2004 2011 (Pubitemid 46211380)
12. Meyers P. A., Schwartz C. L., Krailo M. D., Healey J. H., Bernstein M. L., Betcher D., Ferguson W. S., Gebhardt M. C., Goorin A. M., Harris M., Kleinerman E., Link M. P., Nadel H., Nieder M., Siegal G. P., Weiner M. A., Wells R. J., Womer R. B., Grier H. E., Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survivala report from the children's oncology group Journal of Clinical Oncology 2008 26 4 633 638 (Pubitemid 351264359)
13. Chou A. J., Kleinerman E. S., Krailo M. D., Chen Z., Betcher D. L., Healey J. H., Conrad E. U., Nieder M. L., Weiner M. A., Wells R. J., Womer R. B., Meyers P. A., Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Cancer 2009 115 22 5339 5348
14. Ito H., Murakami K., Yanagawa T., Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Case reports Cancer 1980 46 7 1562 1565 (Pubitemid 10003926)
15. Edmonson J. H., Long H. J., Frytak S., Smithson W. A., Itri L. M., Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas Cancer Treatment Reports 1987 71 7-8 747 748
16. Lauro S., Bordin F., Trasatti L., Lanzetta G., Rocca C. D., Frati L., Concurrent chemoimmunotherapy in metastatic clear cell sarcoma: a case report Tumori 1999 85 6 512 514 (Pubitemid 30074602)
17. Steger G. G., Wrba F., Mader R., Schlappack O., Dittrich C., Rainer H., Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses European Journal of Cancer 1991 27 3 254 256
18. Strander H., Bauer H. C., Brosjo O., Fernberg J. O., Kreicbergs A., Nilsonne U., Silfversward C., Signomklao T., Soderlund V., Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study Acta Oncologica 1995 34 6 877 880
19. Mller C. R., Smeland S., Bauer H. C. F., Ster G., Strander H., Interferon- as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series Acta Oncologica 2005 44 5 475 480 (Pubitemid 41191780)
20. Winkler K., Beron G., Kotz R., Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study Journal of Clinical Oncology 1984 2 6 617 624 (Pubitemid 14025617)
21. Van der Bruggen P., Zhang YI., Chaux P., Stroobant V., Panichelli C., Schultz E. S., Chapiro J., Van den Eynde B. J., Brasseur F., Boon T., Tumor-specific shared antigenic peptides recognized by human T cells Immunological Reviews 2002 188 51 64 (Pubitemid 35398865)
22. Hisaoka M., Ishida T., Kuo T. T., Matsuyama A., Imamura T., Nishida K., Kuroda H., Inayama Y., Oshiro H., Kobayashi H., Nakajima T., Fukuda T., Ae K., Hashimoto H., Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases American Journal of Surgical Pathology 2008 32 3 452 460 (Pubitemid 351398938)
23. Nuciforo P. G., Pellegrini C., Fasani R., Maggioni M., Coggi G., Parafioriti A., Bosari S., Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma Human Pathology 2003 34 7 639 645 (Pubitemid 36875508)
24. Vonderheide R. H., Hahn W. C., Schultze J. L., Nadler L. M., The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes Immunity 1999 10 6 673 679 (Pubitemid 29302920)
25. Reker S., Meier A., Holten-Andersen L., Svane I. M., Becker J. C., Straten P. T., Andersen M. H., Identification of novel survivin-derived CTL epitopes Cancer Biology and Therapy 2004 3 2 173 179 (Pubitemid 41357474)
26. Van Den Eynde B. J., Van Der Bruggen P., T cell defined tumor antigens Current Opinion in Immunology 1997 9 5 684 693 (Pubitemid 27485298)
27. Van den Eynde B., Lethe B., Van Pel A., De Plaen E., Boon T., The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice Journal of Experimental Medicine 1991 173 6 1373 1384
28. Brndle D., Bilsborough J., Rlicke T., Uyttenhove C., Boon T., Van Den Eynde B. J., The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection European Journal of Immunology 1998 28 12 4010 4019 (Pubitemid 28558631)
29. Simpson A. J. G., Caballero O. L., Jungbluth A., Chen Y. T., Old L. J., Cancer/testis antigens, gametogenesis and cancer Nature Reviews Cancer 2005 5 8 615 625 (Pubitemid 41081387)
30. Jungbluth A. A., Antonescu C. R., Busam K. J., Iversen K., Kolb D., Coplan K., Chen Y. T., Stockert E., Ladanyi M., Old L. J., Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7 International Journal of Cancer 2001 94 2 252 256 (Pubitemid 32911421)
31. Skubitz K. M., Pambuccian S., Carlos J. C., Skubitz A. P. N., Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors Journal of Translational Medicine 2008 6 23
32. Ayyoub M., Taub R. N., Keohan M. L., Hesdorffer M., Metthez G., Memeo L., Mansukhani M., Hibshoosh H., Hesdorffer C. S., Valmori D., The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immunity 2004 4 7
33. Ayyoub M., Brehm M., Metthez G., Talbot S., Dutoit V., Taub R. N., Keohan M. L., Gure A. O., Chen Y. T., Williamson B., Jungbluth A. A., Old L. J., Hesdorffer C. S., Valmori D., SSX antigens as tumor vaccine targets in human sarcoma Cancer Immunity 2003 3 13
34. Jacobs J. F. M., Brasseur F., Hulsbergen-van De Kaa C. A., Van De Rakt M. W. M. M., Figdor C. G., Adema G. J., Hoogerbrugge P. M., Coulie P. G., De Vries I. J. M., Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR International Journal of Cancer 2007 120 1 67 74 (Pubitemid 44901919)
35. Geiger J. D., Hutchinson R. J., Hohenkirk L. F., McKenna E. A., Yanik G. A., Levine J. E., Chang A. E., Braun T. M., Mul J. J., Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression Cancer Research 2001 61 23 8513 8519 (Pubitemid 33131133)
36. Mackall C. L., Rhee E. H., Read E. J., Khuu H. M., Leitman S. F., Bernstein D., Tesso M., Long L. M., Grindler D., Merino M., Kopp W., Tsokos M., Berzofsky J. A., Helman L. J., A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas Clinical Cancer Research 2008 14 15 4850
37. Dagher R., Long L. M., Read E. J., Leitman S. F., Carter C. S., Tsokos M., Goletz T. J., Avila N., Berzofsky J. A., Helman L. J., Mackall C. L., Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study Medical and Pediatric Oncology 2002 38 3 158 164 (Pubitemid 34171069)
38. Suminoe A., Matsuzaki A., Hattori H., Koga Y., Hara T., Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors Pediatric Transplantation 2009 13 6 746 753
39. Ullenhag G. J., Spendlove I., Watson N. F. S., Kallmeyer C., Pritchard-Jones K., Durrant L. G., T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55 Clinical Immunology 2008 128 2 148 154
40. Pritchard-Jones K., Spendlove I., Wilton C., Whelan J., Weeden S., Lewis I., Hale J., Douglas C., Pagonis C., Campbell B., Alvarez P., Halbert G., Durrant L. G., Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma British Journal of Cancer 2005 92 8 1358 1365 (Pubitemid 40705000)
41. Kawaguchi S., Wada T., Ida K., Sato Y., Nagoya S., Tsukahara T., Kimura S., Sahara H., Ikeda H., Shimozawa K., Asanuma H., Torigoe T., Hiraga H., Ishii T., Tatezaki S. I., Sato N., Yamashita T., Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma Journal of Translational Medicine 2005 3 1
42. Ida K., Kawaguchi S., Sato Y., Tsukahara T., Nabeta Y., Sahara H., Ikeda H., Torigoe T., Ichimiya S., Kamiguchi K., Wada T., Nagoya S., Hiraga H., Kawai A., Ishii T., Araki N., Myoui A., Matsumoto S., Ozaki T., Yoshikawa H., Yamashita T., Sato N., Crisscross CTL induction by SYT-SSX junction peptide and its HLA- A 2402 anchor substitute Journal of Immunology 2004 173 2 1436 1443 (Pubitemid 38924325)
43. Zhang S., Cordon-Cardo C., Zhang H. S., Reuter V. E., Adluri S., Hamilton WM. B., Lloyd K. O., Livingiston P. O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides International Journal of Cancer 1997 73 1 42 49 (Pubitemid 27445989)
44. Hamilton W. B., Helling F., Lloyd K. O., Livingston P. O., Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography International Journal of Cancer 1993 53 4 566 573 (Pubitemid 23069265)
45. Heiner J. P., Miraldi F., Kallick S., Makley J., Neely J., Smith-Mensah W. H., Cheung N. K. V., Localization of G(D2)-specific monoclonal antibody 3F8 in human osteosarcoma Cancer Research 1987 47 20 5377 5381 (Pubitemid 17152948)
46. Lipinski M., Braham K., Philip I., Neuroectoderm-associated antigens on Ewing's sarcoma cell lines Cancer Research 1987 47 1 183 187 (Pubitemid 17002120)
47. Perez C. A., Ravindranath M. H., Soh D., Gonzales A., Ye W., Morton D. L., Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications Cancer Journal 2002 8 5 384 394
48. Kirkwood J. M., Ibrahim J. G., Sosman J. A., Sondak V. K., Agarwala S. S., Ernstoff M. S., Rao U., High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 Journal of Clinical Oncology 2001 19 9 2370 2380 (Pubitemid 32391207)
49. Dudley M. E., Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens Journal of Clinical Oncology 2008 26 32 5233 5239
50. Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A., Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials Journal of Immunological Methods 1987 102 1 127 141 (Pubitemid 17151559)
51. Balch C. M., Riley L. B., Bae Y. J., Salmeron M. A., Platsoucas C. D., Von Eschenbach A., Itoh K., Patterns of human tumor-infiltrating lymphocytes in 120 human cancers Archives of Surgery 1990 125 2 200 205 (Pubitemid 20060644)